. Author manuscript; available in PMC: 2018 Oct 1.

Published in final edited form as: Eur Neuropsychopharmacol. 2017 Aug 12;27(10):1011–1021. doi: 10.1016/j.euroneuro.2017.07.009

Table 3.

Descriptive statistics of the subject group who received both [¹¹C]DASB (5-HTT tracer) and [¹¹C]WAY-100635 (5-HT_1A tracer) (AE: Exposure to prior antidepressant medication (time off medication: 2‒4 weeks), AN: Antidepressant naïve, NRM: Not recently (>4 years) medicated).

Variables	Levels	Count	Percent (%)
Sex	Female	36	59.02
Sex	Male	25	40.98
MedicationStatus	AE	23	37.70
MedicationStatus	AN & NRM	38	62.30